Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00963820
What this trial is testing

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 60
Testing effectiveness (Phase 2)Study completedNCT03242460
What this trial is testing

The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

Who this might be right for
Relapsed and/or refractorY Multiple Myeloma
Kosin University Gospel Hospital 55
Testing effectiveness (Phase 2)Study completedNCT05064358
What this trial is testing

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 177
Large-scale testing (Phase 3)Not Yet RecruitingNCT07728188
What this trial is testing

Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
AbbVie 520
Large-scale testing (Phase 3)Looking for participantsNCT06561854
What this trial is testing

Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

Who this might be right for
Multiple MyelomaRelapse Multiple Myeloma
Assistance Publique - Hôpitaux de Paris 318
Testing effectiveness (Phase 2)Study completedNCT00793572
What this trial is testing

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Who this might be right for
Refractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 32
Large-scale testing (Phase 3)Study completedNCT03277105
What this trial is testing

Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 522
Testing effectiveness (Phase 2)WithdrawnNCT02986451
What this trial is testing

Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma

Who this might be right for
Relapse/Refractory Multiple Myeloma
Sun Yat-sen University
Large-scale testing (Phase 3)Study completedNCT03110562
What this trial is testing

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc 402
Testing effectiveness (Phase 2)Study completedNCT01427881
What this trial is testing

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)+65 more
Fred Hutchinson Cancer Center 43
Testing effectiveness (Phase 2)UnknownNCT00740467
What this trial is testing

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Institut Paoli-Calmettes 50
Not applicableLooking for participantsNCT07665307
What this trial is testing

Delayed Toxicities Post-CAR-T

Who this might be right for
Multiple Myeloma
Icahn School of Medicine at Mount Sinai 30
Testing effectiveness (Phase 2)Study completedNCT01212952
What this trial is testing

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
Mayo Clinic 50
Testing effectiveness (Phase 2)Study completedNCT00821249
What this trial is testing

ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Pfizer 55
Large-scale testing (Phase 3)Study completedNCT00514371
What this trial is testing

Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 22
Early research (Phase 1)Active Not RecruitingNCT04667663
What this trial is testing

CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

Who this might be right for
Multiple Myeloma
Cancer Trials Ireland 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT07217184
What this trial is testing

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 30
Testing effectiveness (Phase 2)Study completedNCT02654132
What this trial is testing

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 117
Early research (Phase 1)Study completedNCT00006098
What this trial is testing

PS-341 in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT01830816
What this trial is testing

Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Who this might be right for
Multiple MyelomaAdvanced Solid Tumors
Millennium Pharmaceuticals, Inc. 41
Next Page